Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Preeti Srivastava

Nurse Practitioner, Psychiatric/Mental Health Nashville, TN Nurse Practitioner

NPI 1043806516 CMS profile 8794492

123 Brighton Close, Nashville, TN 37205

Open in the dashboard

General payments

$11,207

724 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Preeti Srivastava of Nashville, TN is reported in the CMS Open Payments database as having received $11,207 across 724 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,721 214
2024 General $2,456 170
2023 General $2,592 192
2022 General $1,840 125
2021 General $598 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Preeti Srivastava
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Preeti Srivastava were reported at $3,721. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Preeti Srivastava Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $598 $166 $54–$482 $132
2022 $1,840 $195 $66–$559 $149
2023 $2,592 $233 $82–$673 $160
2024 $2,456 $236 $84–$688 $164
2025 $3,721 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Supernus Pharmaceuticals, Inc. $1,803 178 payments
  2. Neurocrine Biosciences, Inc. $1,157 55 payments
  3. Alkermes, Inc. $1,063 60 payments
  4. Otsuka America Pharmaceutical, Inc. $829 58 payments
  5. AbbVie, Inc. $778 76 payments
  6. Vanda Pharmaceuticals Inc. $727 28 payments
  7. Janssen Pharmaceuticals, Inc $687 47 payments
  8. ITI, Inc. $651 36 payments
  9. Axsome Therapeutics, Inc. $601 27 payments
  10. E.R. Squibb & Sons, L.L.C. $494 18 payments
  11. Other $2,415 141 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,157 722 payments
  2. Education $50 2 payments
Products named General payments · program years 2021–2025
  1. LYBALVI $1,063 60 payments
  2. Qelbree Viloxazine Hydrochloride $927 90 payments
  3. QELBREE Psychology $876 88 payments
  4. INGREZZA $806 45 payments
  5. FANAPT $727 28 payments
  6. REXULTI $681 48 payments
  7. ARISTADA Cns $661 35 payments
  8. ARISTADA Cns $661 35 payments
  9. VRAYLAR $578 55 payments
  10. Auvelity $553 25 payments
  11. Other $8,180 460 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,286

Median for Nurse Practitioner: 389

Drug cost

$78,012

Median for Nurse Practitioner: $21,885

Branded share of claims

23.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 12 $19,892
Rexulti Brexpiprazole Brand 12 $18,691
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 91 $7,394
Vyvanse Lisdexamfetamine Dimesylate Brand 14 $5,080
Bupropion Xl Bupropion Hcl Brand 88 $3,623
Duloxetine Hcl Generic 86 $2,729
Atomoxetine Hcl Generic 16 $2,065
Aripiprazole Generic 57 $2,059
Lisdexamfetamine Dimesylate Generic 12 $1,751
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 35 $1,690

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$13,892

Medicare's payments for the services billed

Medicare patients

33

Average age 69

Services billed

233

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Depression 70%
Arthritis 61%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $580
$580 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $219
$219 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $134
  • Lundbeck LLC $69
$203 12 —
VRAYLAR
  • AbbVie, Inc. $200
$200 12 —
ARISTADA
  • Alkermes, Inc. $163
$163 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

724 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record